STVN - KeyBanc lists beneficiaries in life sciences as Omicron drives demand for PCR tests vaccines

A group of analysts from KeyBank Capital Markets has named several life sciences companies that could benefit from renewed demand for PCR tests and COVID-19 vaccines after the emergence of the newly detected Omicron variant. While noting that it is too early to identify the impact of the variant on patient risk and vaccine-driven immunity, the analysts led by Paul Knight project a softer-than-anticipated decline for PCR testing in 2022. The firm names Danaher (DHR +0.9%), Thermo Fisher (TMO +2.0%), and PerkinElmer (PKI +1.6%) as companies which are highly leveraged for PCR testing in its sector coverage. The analysts also cite positive remarks issued by the management of Lonza Group (OTCPK:LZAGY -0.7%), (OTCPK:LZAGF) Stevanato (NYSE:STVN), and Danaher (NYSE:DHR) over the potential to fill the void created by low COVID-19 vaccination rates in developing markets. Expecting the progression of lower or single dose formats from six dose vials at Pfizer (NYSE:PFE)

For further details see:

KeyBanc lists beneficiaries in life sciences as Omicron drives demand for PCR tests, vaccines